Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M2X3bWNmdGxiVnnhZoltcXS7IFHzd4F6 NHKzb2sxNTBwNTFOwG0> MX[yOEBp M2L1VYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NHHCV2ozPTZ4M{e2PS=>
HepG2-HBV1.1 NHTDfXhCeG:ydH;zbZMhSXO|YYm= M321dVAuOC53IN88US=> NXLId|U4OjRiaB?= MoXabY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MlLpNlU3PjN5Nkm=
HepG2.2.15 MmrxSpVv[3Srb36gRZN{[Xl? MWWwMlEh|ryP MlrqNlQhcA>? NX\ZdmdmeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v NH3CXGwzPTZ4M{e2PS=>
HepG2-HBV1.1 MYjGeY5kfGmxbjDBd5NigQ>? Ml3uNE4yKM7:TR?= NIXWfIgzPCCq NX3rW2R7eHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v M2jYNlI2PjZ|N{[5
HepG2-HBV1.1 NEPqZohHfW6ldHnvckBCe3OjeR?= NIXsfWsxNjFizszN NVnmcndpPDhiaB?= MmXGdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ MXOyOVY3Ozd4OR?=
HepG2-HBV1.1 M1TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfFXplNOC5zIN88US=> M2H5XlEuPSCm NX3HT4s2cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> MVuyOVY3Ozd4OR?=
HepG2-HBV1.1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrCbJBWOC5zIN88US=> MXyxMVUh\A>? MkX0bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MmXVNlU3PjN5Nkm=
HepG2-HBV1.1 M{XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DXUVAvOSEQvF2= MXKxNk04OiCq Mo\HbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl NY\tfXlFOjV4NkO3Olk>
HepG2-HBV1.1 M4PPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXXlAvOSEQvF2= NHGycpUyOi15MjDo MUjpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W= MlLwNlU3PjN5Nkm=
Raji NYnyTFRETnWwY4Tpc44hSXO|YYm= M2SzNVAvPcLizszN MYm3NkBp NF:5b4di[m:uaYPo[ZMh[XW2b4DoZYd6yqB? M4W2NFI2PDR4M{e3
SK-MEL-28  M{\zc2Z2dmO2aX;uJGF{e2G7 NX3zb2h7OzBibl2= MXS2JIg> NFrQVHdqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW|dB?= NE\0[mYzPTNzM{CxNC=>
H157 NUD6PIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWxTWM2OD1zLkCzJOKyKDBwMESgcYl2Ok1? NEPQPGIzPTJ3N{mxNS=>
Jurkat NIDrRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexMVMhdk1? NWrTOos1PDkEoHi= MVzEUXNQ MVfk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 M4K5elI2OTV4MUS2
CEM Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTTeYtWOS1|IH7N MmrrOFjDqGh? M4[3b2ROW09? NUn0R292\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? NXzN[IRWOjVzNU[xOFY>
P12 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLtNU0{KG6P NXfGc5BvPDkEoHi= NV;xVYdpTE2VTx?= M4T5UIRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NVL4XHYzOjVzNU[xOFY>
KB MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH72OnpKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NXHLTIRLOjVyNUi1NlY>
KBv200 (ABCB1) NGnCNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP2WZhKSzVyPUCuN|Q3OiEEsTCwMlAxPjZizszN MlzJNlUxPTh3Mk[=
SUDHL6  NX;m[mZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DheVHjiIoQvF2= M4PiTVQ5Nzd{IHi= MkDWbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MUiyOFk3OTZyNB?=
SUDHL6  MX\GeY5kfGmxbjDBd5NigQ>? MXyx5qCK|ryP MmfjO|IhcA>? MUHpcoR2[2W|IIPp[45q\mmlYX70JIFxd3C2b4TpZ{Bud3KyaH;sc4d6KGOqYX7n[ZMh[2:2cnXzeIVlKHerdHigRmNNOTGDIIPpVm5C MoTiNlQ6PjF4MES=
HCT-116 NGKzdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\YWGdKPTB;NTDuUS=> NX;2VFl[OjR7Mke4OVc>
SKNBe2C MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnTVnRKSzVyPUOyMljDuTRwMDDuUS=> MknoNlQ6OjF7MkC=
IGNR91 NV3kd2F6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqxTWM2OD1{ND6zxtEyNjdibl2= MmK4NlQ6OjF7MkC=
SKNAS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnXO2lVUUN3ME2xMlXDuTBwMjDuUS=> M13tWlI1QTJzOUKw
LAN1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwM9MxNE4zKG6P NF7jPG4zPDl{MUmyNC=>
SHSY5Y NWLaeIFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVyxeVRQUUN3ME24MlLDuTBwNjDuUS=> NFHQdXYzPDl{MUmyNC=>
A549-WT NITINI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? MWOyOFg2QDh{Nx?=
A549-R MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\n[2lEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= MWWyOFg2QDh{Nx?=
MCF-7-WT M3f5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf0TWM2OD1zNz63OVIhyrFiMD6yNVghKG6P MlLwNlQ5PTh6Mke=
MCF-7-R M{K4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PaXmlEPTB;NT61N|khyrFiMD6xOFQhKG6P NXvO[IJpOjR6NUi4Nlc>
A549-R NVjVU3BwS3m2b4TvfIlkcXS7IFHzd4F6 MYLJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? NIXEfJYzPDh3OEiyOy=>
MCF-7-R MlWxR5l1d3SxeHnjbZR6KEG|c3H5 NES2b2pKSzVyPUWuOVM6KMLzIECuNVQ1KG6P NFXnW4ozPDh3OEiyOy=>
SW620 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HISmlEPTB;Nz64NEDDuSByLkC4JI5O MUeyOFczPjd|OR?=
SW620/AD300 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlyOT62NEDDuSB6LkmxJI5O MUmyOFczPjd|OR?=
HEK293/pcDNA3.1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwNEWgxtEhOC5{MDDuUS=> M1\rZVI1PzJ4N{O5
HEK293/ABCC1 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXBZYlPUUN3ME2xPU4zQSEEsTCyMlA5KG6P MWqyOFczPjd|OR?=
TCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XBRlI1KGh? MoLoTWM2OD15MDDuUS=> MUKyOFcyPjl2NB?=
TCC MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV20PEBp NHKwTHVKSzVyPUWwJI5O NEjHOmQzPDdzNkm0OC=>
HepG2/ADM MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvxbnl[UUN3ME2yMlc5PjQEsUCuNlM4OSEQvF2= NV7nUpdkOjR5MES1OVY>
HepG2 M1y0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? NFnSZpUzPDdyNEW1Oi=>
MCF-7/ADR MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfIVlFKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= NGrnOGQzPDdyNEW1Oi=>
MCF-7 M1;vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e2OWlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP M1nhcFI1PzB2NUW2
A-172  NG\hTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWwNE4yyqEQvF2= M1O5OFI1Nzd{IHi= NIrQOGZqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 NF;vNI8zPDV|MEKzOS=>
U-251MG MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS5NE4yyqEQvF2= MVyyOE84OiCq M3v1eYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> M1qweFI1PTNyMkO1
DLD-1 NEXZS4RHfW6ldHnvckBCe3OjeR?= M{WzXVExOCCwTR?= NXG4R3lpPDhiaB?= M3fJdJBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? Ml;zNlQ1ODN2NUO=
CCD18Co NFHxcZNHfW6ldHnvckBCe3OjeR?= NV3JPINlOTByIH7N Mmm3OFghcA>? M1ezbJBzd22xdHXzJHJWVlh|IHTlcYV1cHmuYYTpc47DqA>? NFrCW|IzPDRyM{S1Ny=>
DLD-1 NGPtRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj3N4d5OC1zMECwJI5O NGf5RWo1QCCq Mn3ObY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NEPK[WEzPDRyM{S1Ny=>
CCD18Co MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMVExODBibl2= M4\jclQ5KGh? MVzpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MX[yOFQxOzR3Mx?=
HepG2 M{faS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TtW|I1KGh? M{HVfWlEPTB;NUKuOgKBkc7:TR?= NGTOTHMzPDN2MU[4PC=>
HEK293/pcDNA3.1 M37WeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne1TWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? M3jWXVI1Ojh2N{iz
HEK293/MRP1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\wbZlyUUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= NHfZbWczPDJ6NEe4Ny=>
Ramos MX;BdI9xfG:|aYOgRZN{[Xl? MnnDNwKBkc7:TR?= NHy1UJI1QCCq NHPGPVFqdmS3Y3XzJFM1NjZnwsGxMlkzLSCjcH;weI9{cXN? M1HJVVI1OjV4NEmx
NCI-H1299/pcDNA3 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1jI[VAuOjBibl2= MXO5OkBp NIH0TXZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYLJbm1wOjRzN{ewNVI>
H1299/ICAM-3 MmnYR4VtdCCYaXHibYxqfHliQYPzZZk> MWCwMVIxKG6P M4j1Wlk3KGh? M1nnfolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M{XHTVI1OTd5MEGy
NCI-H1299/pcDNA3 NXGyTG01TnWwY4Tpc44hSXO|YYm= MoTDNU82NzFyL{KwxsBvVQ>? NWfrSHBMQTZiaB?= M2XZZYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> MlvINlQyPzdyMUK=
H1299/ICAM-3 NF\PUXJHfW6ldHnvckBCe3OjeR?= MWixM|UwOTBxMkFCpI5O NV\5blc3QTZiaB?= NY[xfYpycW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? MmrSNlQyPzdyMUK=
W1 NYrifplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMECzNkDPxE1? NV3GXVRkOjRzNECxO|Y>
W1VR MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfXUVRKSzVyPUCuNFU3KM7:TR?= Mn7HNlQyPDBzN{[=
K562 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jDZmlEPTB;MD6wN|IhyrFiMD6wNFEhKM7:TR?= NFLXe4QzPDF|NUmzOy=>
K562/ADR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWThR3FEUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= MoPkNlQyOzV7M{e=
K562 MULBdI9xfG:|aYOgRZN{[Xl? M4PseFAvOyEQvF2= NGXielIzPCCq M2[4bIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NXPD[IxDOjRzM{W5N|c>
K562/ADR NIq4cVJCeG:ydH;zbZMhSXO|YYm= MWCzJO69VQ>? M1zWb|I1KGh? MoT4bY5lfWOnczDhdI9xfG:|aYO= M1P3VVI1OTN3OUO3
A549 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMUCgxtEhOC5yMzFOwG0> NV74W4FZOjN7N{GwO|U>
K562 M3vCTWNmdGxiVnnhZoltcXS7IFHzd4F6 MnH1N{44PeLCk{[wxsBvVQ>? Mki1O|LDqGkEoB?= NILheYFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVjuOlZEOjN6N{eyNlM>
lucena M3XCPWNmdGxiVnnhZoltcXS7IFHzd4F6 MmLRN{44PeLCk{[wxsBvVQ>? NELC[Ho4OsLiaNMg MXXuc{Bm\m[nY4S= NFHqNFIzOzh5N{KyNy=>
FEPS M17xRmNmdGxiVnnhZoltcXS7IFHzd4F6 MVuzMlc26oDVNkFCpI5O NXriVnlXPzMEoHlCpC=> NXXYcmh5dm9iZX\m[YN1 MVqyN|g4PzJ{Mx?=
A2780 NH7hTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHWXVhHUUN3ME2zMlUhdU1? Mo[wNlM5Ojl{MEO=
ACHN Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRDBwMTDtUS=> M1TocFI{QDJ7MkCz
U-937 M4H4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HqdWlEPTB:M{Sgcm0> MY[yN|gzQTJyMx?=
Jurkat NU\xUnN7SXCxcITvd4l{KEG|c3H5 NYP0d3htPcLizsznM41tyqB? NVLze3pZOjRiaB?= MoXmbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MYKyN|gyODRyOR?=
Jurkat Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDuOVQ2yqEQvHevcYzDqA>? MUSyOEBp M3jn[YFzemW|dDDKeZJs[XRiY3XscJMhcW5iR{KvUUBxcGG|ZR?= NEjERlIzOzhzMESwPS=>
Hep-2 NWPwVG42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnWd25KSzVyPUCuNFTDuTBwMEGg{txO M4CwXVI{PzhyNEK0
Hep-2/v NVOwZmY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1zLklCtVAvOjBizszN MkTCNlM4QDB2MkS=
SGC-7901 M37OWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHNE0yOCEQvHevcYw> MoHUNlQwPDhxN{KgbC=> MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MmfXNlM4PDN3N{K=
SGC-7901/VCR M2G0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rJblAuOTBizsznM41t NHm5foMzPC92OD:3NkBp MoTNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MmDUNlM4PDN3N{K=
SGC-7901 NYXkNoFpSXCxcITvd4l{KEG|c3H5 M1PrXYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? MmD5NlM4PDN3N{K=
SGC-7901/VCR M4jrTWFxd3C2b4Ppd{BCe3OjeR?= NHPBTZpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M4nJRVI{PzR|NUey
KB-3-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjzWJNKSzVyPUGuOlYhyrFiMD6xOlIh|ryP NIH5VHIzOzZ5M{S0OS=>
KB-C2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHkTWM2OD1{MEKuOVYhyrFiNEKuOFgyKM7:TR?= M2KxcVI{Pjd|NES1
KB-3-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\RNIlEUUN3ME2xMlI3KMLzIECuNFI4KM7:TR?= Mn;3NlM3PzN2NEW=
KB-V1 NFW5[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nMVGlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP MonoNlM3PzN2NEW=
HEK293/pcDNA3.1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;mTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NXiyUJJiOjN4N{O0OFU>
HEK293/ABCB1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTN3MUKuPEDDuSB|N{iuN|kyKM7:TR?= MmOxNlM3PzN2NEW=
A549/EGFP  MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDFNE4xOS1zMECwJO69VQ>? MXTJR|UxRTh4LkegxtEhOjlwMTFOwG0> MmfPNlM3OzR{OEK=
A549/Slug NFjw[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T1WVAvODFvMUCwNEDPxE1? NWe5Zm1yUUN3ME25MlchyrFiMz6xJO69VQ>? NUfOXYpUOjN4M{SyPFI>
JFCR39  MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG4boQyKML3TR?= NHzKSIMzPCCq MYjEUXNQ MUXtZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ NYHiSpFWOjN3OUiyO|Y>
A549 M3P6TmZ2dmO2aX;uJGF{e2G7 MVKxNFAhdk1? NHHneJAyPiCq Mkm0SG1UVw>? MnL6cIVi\HNidH:gZUBtd3O|IH;mJI1q[3KxdIXieYxmew>? NG\XUmIzOzV7OEK3Oi=>
SGC7901 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGzNWx{UUN3ME2xMlI36oDLwsJihKkxNjFzIN88[{9udA>? MmLhNlM2PjR2OEK=
SGC7901/LV-NC MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXZTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> MoC1NlM2PjR2OEK=
SGC7901/LV-SGO1 M1j5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH3NIdoUUN3ME20MlM36oDLwsJihKkxNjN5IN88[{9udA>? NU[1XoFLOjN3NkS0PFI>
SGC7901/VCR NHTwUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL1cmNKSzV|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>? M1vTVVI{PTZ2NEiy
SGC7901/VCR-NC MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TVWlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t MUWyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 NGHaXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s MmPhNlM2PjR2OEK=
SGC7901/ADR NIfWdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTIfHBiUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? MWqyN|U3PDR6Mh?=
SGC7901/ADR-NC M{G1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjjWlJoUUN3ME24Mlk{6oDLwsJihKkxNjZ6IN88[{9udA>? NUWy[WJWOjN3NkS0PFI>
SGC7901/ADR-si-SGO1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;kR4tQUUN3ME2zMlQ36oDLwsJihKkxNjJ7IN88[{9udA>? NGXnWGMzOzV4NES4Ni=>
SH-SY5Y  NG\CR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCwMlAxOS1zMDFOwG0> MlTwNlQhcA>? MX\JR|UxRTBwMUGzxtExNjBzMjFOwG0> M2fuTlI{OTJ7ME[1
SH-SY5Y  M{G3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoZYYxNjByMT2xNEDPxE1? NGLNeFg1QCCq NHHqbXdKSzVyPUCuNFc5yrFyLkCwPUDPxE1? MlnhNlMyOjlyNkW=
SH-SY5Y  MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2yTIJWOC5yMEGtNVAh|ryP NELJXGc4OiCq NXPubHdkUUN3ME2wMlA2OcLzMD6wNFgh|ryP M3fobFI{OTJ7ME[1
SH-SY5Y MVLBdI9xfG:|aYOgRZN{[Xl? NVn2R3dCOC5zIN88US=> Mn23NE0zPCCq NYO2fnNbcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> NV\NSI45OjNzMkmwOlU>
SH-SY5Y MWrBdI9xfG:|aYOgRZN{[Xl? MlLwNE4yKM7:TR?= NVrpdpFxOC1{NDDo Mm\VbY5lfWOnczDtbZRwfGmlIHHydoV{fMLi NY\EN3NZOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami June 2019 Phase 1
NCT03871257 Not yet recruiting Low Grade Glioma|Neurofibromatosis Type 1|Visual Pathway Glioma National Cancer Institute (NCI) May 3 2019 Phase 3
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID